Literature DB >> 15123043

The hereditary amyloidoses.

Merrill D Benson1.   

Abstract

Hereditary amyloidosis is, in general, a systemic condition related to multiple organ system involvement by beta-structured protein deposits. As such, it often mimics the more common forms of systemic amyloidosis: immunoglobulin light chain (AL, primary) and reactive (AA, secondary). The challenge diagnostically is to recognize hereditary amyloidosis as a distinct entity and then to determine the specific type of genetic disease. There are several types of hereditary amyloidosis and precise diagnosis is essential for proper therapy and genetic counselling. This chapter strives to present the subject of hereditary amyloidosis in a way which facilitates understanding of the disease, of the means for diagnosis, of the present and possible future therapies, and of the importance of combined basic and medical research.

Entities:  

Mesh:

Year:  2003        PMID: 15123043     DOI: 10.1016/j.berh.2003.09.001

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  22 in total

1.  Role of imaging in cardiac amyloidosis: An ongoing challenge.

Authors:  Ashutosh D Wechalekar
Journal:  J Nucl Cardiol       Date:  2015-11-05       Impact factor: 5.952

Review 2.  [Amyloid and amyloidoses].

Authors:  C Röcken; M Eriksson
Journal:  Pathologe       Date:  2009-05       Impact factor: 1.011

Review 3.  Fibrinogen alpha amyloidosis: insights from proteomics.

Authors:  Jessica Chapman; Ahmet Dogan
Journal:  Expert Rev Proteomics       Date:  2019-08-28       Impact factor: 3.940

4.  Mass spectrometry analysis reveals non-mutated apolipoprotein A1 lumbosacral radiculoplexus amyloidoma.

Authors:  Adam J Loavenbruck; Vinay Chaudhry; Steven R Zeldenrust; Robert J Spinner; Jason D Theis; Christopher J Klein
Journal:  Muscle Nerve       Date:  2012-11       Impact factor: 3.217

5.  The amyloidoses: clinical features, diagnosis and treatment.

Authors:  Kelty R Baker; Lawrence Rice
Journal:  Methodist Debakey Cardiovasc J       Date:  2012 Jul-Sep

6.  Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.

Authors:  Teresa Coelho; Luis F Maia; Ana Martins da Silva; Marcia Waddington Cruz; Violaine Planté-Bordeneuve; Pierre Lozeron; Ole B Suhr; Josep M Campistol; Isabel Maria Conceição; Hartmut H-J Schmidt; Pedro Trigo; Jeffery W Kelly; Richard Labaudinière; Jason Chan; Jeff Packman; Amy Wilson; Donna R Grogan
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

Review 7.  Role of imaging in the diagnosis and management of patients with cardiac amyloidosis: state of the art review and focus on emerging nuclear techniques.

Authors:  Wael A Aljaroudi; Milind Y Desai; W H Wilson Tang; Dermot Phelan; Manuel D Cerqueira; Wael A Jaber
Journal:  J Nucl Cardiol       Date:  2014-04       Impact factor: 5.952

Review 8.  Nuclear imaging in cardiac amyloidosis.

Authors:  A W J M Glaudemans; R H J A Slart; C J Zeebregts; N C Veltman; R A Tio; B P C Hazenberg; R A J O Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-21       Impact factor: 9.236

9.  Incidence and survival in non-hereditary amyloidosis in Sweden.

Authors:  Kari Hemminki; Xinjun Li; Asta Försti; Jan Sundquist; Kristina Sundquist
Journal:  BMC Public Health       Date:  2012-11-13       Impact factor: 3.295

Review 10.  Renal amyloidosis in children.

Authors:  Yelda Bilginer; Tekin Akpolat; Seza Ozen
Journal:  Pediatr Nephrol       Date:  2011-03-01       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.